Premature ovarian failure: Long-term sequelae

Menopause International

Volumn 16, Issue 1, 2010, Pages 38-41

  Maclaran, Kate ^a,b   Horner, Etienne ^b   Panay, Nick ^c  

^a QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

hormone replacement therapy; premature menopause; Premature ovarian failure

Indexed keywords

ESTROGEN;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COGNITION; EARLY MENOPAUSE; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FERTILITY; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; MORBIDITY; MORTALITY; OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; PSYCHOLOGICAL ASPECT; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

AGE OF ONSET; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE, PREMATURE; OVARIAN FAILURE, PREMATURE; QUALITY OF LIFE; RISK; TIME FACTORS;

EID: 77951753007     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2010.010014     Document Type: Review

References (37)

1. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67: 604–606
2. Vujovic S. Aetiology of premature ovarian failure. Menopause Int 2009; 12: 72–75
3. Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99: 720–725
4. Panay N, Kalu E. Management of premature ovarian failure. Best Prac Res Clin Obstet Gynaecol 2009; 23: 129–40
5. Rebar RW. Premature ovarian failure. Obstet Gynecol 2009; 113: 1355–63
6. Sowers MR, Eyvazzadeh AD, McConnell D,, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93: 3478–83
7. Kalu E, Panay N. Spontaneous premature ovarian failure: management challenges. Gynaecol Endocrinol 2008; 24: 273–279
8. Kalantaridou SN, Nelson LM. Premature ovarian failure is not premature menopause. Ann NY Acad Sci 2000; 900: 393–402
9. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 3040–3
10. Ng C, Sacks G, Turner C. Impact of alarmist media on HRT use for premature menopause [Abstracts of the 20th Meeting of the ESHRE, Berlin, Germany]. Hum Reprod 2004; i142
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321–33
12. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999; 52: 303–307
13. Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16: 556–62
14. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7: 821–828
15. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89: 157–61
16. L⊘kkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006; 53: 226–33
17. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007; 14: 373–84
18. Merz CN, Johnson BD, Sharaf BL,, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE Study. J Am Coll Cardiol 2003; 41: 413–419
19. Kalantaridou SN, Naka KK, Papanikolaou E,, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89: 3907–13
20. Knauff EA, Westerveld HE, Goverde AJ,, et al. Lipid profile of women with premature ovarian failure. Menopause 2008; 15: 919–23
21. Corrigan EC, Nelson LM, Bakalov VK,, et al. Effects of ovarian failure and X-chromosome deletion on body composition and insulin sensitivity in young women. Menopause 2006; 13: 911–916
22. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010; 65: 262–266
23. Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavorable lipid levels and increased cardiovascular risk. Hum Reprod 2003; 18: 1570–3
24. Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91: 12–15
25. Uygur D, Sengul O, Bayar D,, et al. Bone loss in young women with premature ovarian failure. Arch Gynaecol Obstet 2005; 273: 17–19
26. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003; 14: 525–30
27. van der Klift M, de Laet CE, McCloskey EV,, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 2004; 19: 1172–80
28. Rocca WA, Bower JH, Maraganore DM,, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69: 1074–83
29. Rocca WA, Bower JH, Maraganore DM,, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70: 200–209
30. Schmidt PJ, Cardoso GM, Ross JL, Haq N, Rubinow DR, Bondy CA. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 2006; 295: 1374–6
31. Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. J Psychosom Obstet Gynaecol 2000; 21: 167–74
32. van der Stege JG, Groen H, van Zadelhoff SJ,, et al. Decreased androgen concentrations and diminishes general and sexual well-being in women with premature ovarian failure. Menopause 2008; 15: 23–31
33. Orshan SA, Ventura JL, Covington SN, Vanderhoof VH, Troendle JF, Nelson LM. Women with spontaneous 46,XX primary ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. Fertil Steril 2009; 92: 688–93
34. Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause 2004; 11: 766–77
35. LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988; 16: 115–22
36. Betterle C, Volpato M, Rees Smith B,, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82: 932–938
37. van Karseren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5: 483–92